Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.endPage2341
UDC.grupoInvGrupo de Investigación Cardiovascular (GRINCAR)
UDC.grupoInvInsuficiencia Cardíaca Avanzada e Transplante Cardíaco (INIBIC)
UDC.institutoCentroCIF - Campus Industrial de Ferrol
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue19
UDC.journalTitleEuropean Heart Journal
UDC.startPage2326
UDC.volume47
dc.contributor.authorLund, Lars H.
dc.contributor.authorMaggioni, Aldo P.
dc.contributor.authorCrespo-Leiro, María Generosa
dc.contributor.authorLaroche, Cécile
dc.contributor.authorGostman, Israel
dc.contributor.authorPojskic, Belma
dc.contributor.authorVataman, Eleonora
dc.contributor.authorGrigorica, Lucica
dc.contributor.authorSisakian, Hamayak
dc.contributor.authorGlavas, Duska
dc.contributor.authorBrito, Dulce
dc.contributor.authorAnker, Stefan
dc.contributor.authorChioncel, Ovidiu
dc.contributor.authorFilippatos, Gerasimos
dc.contributor.authorLainscak, Mitja
dc.contributor.authorMcDonagh, Theresa
dc.contributor.authorMebazaa, Alexandre
dc.contributor.authorPiepoli, Massimo
dc.contributor.authorRuschitzka, Frank
dc.contributor.authorSavarese, Gianluigi
dc.contributor.authorSeferovic, Petar M.
dc.contributor.authorMetra, Marco
dc.contributor.authorRosano, Giuseppe
dc.date.accessioned2026-05-28T10:53:38Z
dc.date.available2026-05-28T10:53:38Z
dc.date.issued2026-02-25
dc.descriptionMulticenter study
dc.description.abstract[Abstract] Background and aims: To assess in-hospital and 1-year cause-specific outcomes in the contemporary European Society of Cardiology (ESC) Heart Failure (HF) III Registry. Methods: Patients were enrolled in European or ESC affiliated countries and characterized in detail regarding clinical characteristics and cause-specific outcomes. Results: Between 1 November 2018 and 31 December 2020, 10,162 patients were enrolled from 220 centres in 41 countries. Of these, 39% had acute HF ('AHF', age 70 [62-79] years, 36% women) and 61% had out-patient visit for HF ['out-patient HF', age 66 (58-75) years, 33% women]. Overall, 58% had HF with reduced ejection fraction (HFrEF), 17% HF with mildly reduced ejection fraction (HFmrEF), and 25% HF with preserved ejection fraction (HFpEF). In AHF, median [interquartile range (IQR)] duration of hospitalization was 9 (6-14) days, and 5.1% died in hospital (HFrEF 5.2%; HFmrEF 4.8%, HFpEF 3.4%). In AHF discharged alive and in out-patient HF, after a median (IQR) follow-up of 376 (360-432) days, all-cause, cardiovascular (CV), and unknown-cause mortality rates per 100 patient-years were as follows: AHF HFrEF: 19, 13, and 3.0 per 100 patient-years. The corresponding numbers were in AHF HFmrEF: 22, 11, and 6.3; AHF HFpEF: 16, 7.0, and 4.7; out-patient HFrEF: 6.6, 4.3, and 0.9; out-patient HFmrEF: 4.0, 2.6, and 0.8; out-patient HFpEF: 3.9, 1.7, and 1.2. At least one (re-)hospitalization for HF was experienced in 44% AHF HFrEF, 42% AHF HFmrEF, 36% AHF HFpEF, 21% out-patient HFrEF, 14% out-patient HFmrEF, and 18% out-patient HFpEF. Conclusions: In HF in Europe and affiliated countries, in-hospital mortality was 5.1% and greater with lower ejection fraction. Among hospital survivors and out-patients over 1 year of follow-up, event rates per 100 patient-years varied for death, 3.9-22, CV death 1.7-13, and unknown cause of death 0.8-6.3. The percent of patients that were (re-)hospitalized for HF at least once over 1-year follow-up ranged 14-44% and was twice as high post-AHF compared with post-out-patient visit.
dc.description.sponsorshipThis work was supported by the following companies since the start of EORP and for the period of the HF III study: Abbott Vascular Int. (2018–2021), Amgen Cardiovascular (2016–2018), AstraZeneca AB (2017–2020), Bayer AG (2016–2018), Boehringer Ingelheim (2016–2019), Bristol Myers Squibb (2017–2019), Daiichi Sankyo Europe GmbH (2017–2020), Edwards Lifesciences (2016–2019), Novartis Pharma AG (2018–2020), Servier (2015–2021), and Vifor (2019–2021).
dc.identifier.citationLund LH, Maggioni AP, Crespo-Leiro MG, Laroche C, Gotsman I, Pojskic B, Vataman EB, Grigorica L, Sisakian H, Glavas D, Brito DA, Anker S, Chioncel O, Filippatos G, Lainscak M, McDonagh TA, Mebazaa A, Piepoli M, Ruschitzka F, Savarese G, Seferović PM, Metra M, Rosano G; ESC EORP HF III National Leaders and Investigators. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. Eur Heart J. 2026 May 18;47(19):2326-2341.
dc.identifier.doi10.1093/eurheartj/ehaf1074
dc.identifier.issn0195-668X
dc.identifier.urihttps://hdl.handle.net/2183/48406
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.urihttps://doi.org/10.1093/eurheartj/ehaf1074
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAcute heart failure
dc.subjectChronic heart failure
dc.subjectEjection fraction
dc.subjectEvent rates
dc.subjectOutcomes
dc.subjectRegistry
dc.subjectTrial design
dc.titleOutcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication36d178fd-10a0-48a2-925d-71d185a50eda
relation.isAuthorOfPublication.latestForDiscovery36d178fd-10a0-48a2-925d-71d185a50eda

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lund_Outcomes_2026.pdf
Size:
3.82 MB
Format:
Adobe Portable Document Format